Literature DB >> 2890307

A comparative trial of pharmacologic strategies in schizophrenia.

W T Carpenter1, D W Heinrichs, T E Hanlon.   

Abstract

An open comparative trial was conducted involving 42 schizophrenic outpatients randomly assigned to one of two methods of drug administration: continuous medication (N = 21) and targeted medication plus psychosocial intervention (N = 21). The results, which suggest an extensive similarity with respect to outcome for the two treatments over a 2-year period, argue for the continuation of research on the relative effectiveness of the targeted drug approach, particularly in cases judged suitable for drug reduction strategies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890307     DOI: 10.1176/ajp.144.11.1466

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

Review 1.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 2.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  William T. Carpenter Jr: 35 years of clinical trials.

Authors:  Robert W Buchanan
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

Review 4.  Continuous versus intermittent neuroleptic therapy in schizophrenia.

Authors:  A G Jolley; S R Hirsch
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

5.  Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.

Authors:  A G Jolley; S R Hirsch; A McRink; R Manchanda
Journal:  BMJ       Date:  1989-04-15

6.  Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

Authors:  Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

Review 7.  Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.

Authors:  Nancy Sohler; Ben G Adams; David M Barnes; Gregory H Cohen; Seth J Prins; Sharon Schwartz
Journal:  Am J Orthopsychiatry       Date:  2015-12-14

8.  Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.

Authors:  A G Jolley; S R Hirsch; E Morrison; A McRink; L Wilson
Journal:  BMJ       Date:  1990-10-13

9.  Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Authors:  Hyun-Ghang Jeong; Moon-Soo Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.